OB/GYNs Find Diagnostic Value in VAP® Cholesterol Test

Comprehensive lipid profile demonstrated by Atherotech Diagnostics Lab at South Central Obstetrical & Gynecological Society’s 52nd Annual Meeting

BIRMINGHAM, Ala.--(BUSINESS WIRE)-- Atherotech Diagnostics Lab will attend the South Central Obstetrical & Gynecological Society (SCOGS) 52nd Annual Meeting held this week in Charlottesville, Va. Atherotech representatives will demonstrate the company’s patented VAP^® (Vertical Auto Profile) Test and offer blood draws to qualified attendees.

Developed by Atherotech (www.atherotech.com), the VAP Cholesterol Test plays a central role in women’s health issues such as PCOS, infertility, post- and peri-menopause and cardiovascular risk. Within the last year, the number of obstetricians and gynecologists ordering the VAP Test has grown rapidly, and the number of women who have received VAP Tests from this physician-market has tripled.

Unlike the standard cholesterol test, the advanced panel measures a range of cholesterol subclasses and can be administered without fasting. The VAP Test is widely covered by insurance, and results have shown a correlation between patients who have PCOS and low levels of HDL₂, a highly protective subclass of high density lipoprotein (HDL). It also identifies markers of metabolic syndrome, often associated with early diabetes.

“The VAP Test is a more accurate lipid profile and allows OB/GYN physicians to initiate treatment or refer patients for specialized care,” said Steven Foley, M.D., a Colorado Springs, Colo., gynecologist who specializes in the identification and treatment of patients suffering from PCOS.

The VAP Test is the only expanded lipid test that routinely reports directly measured LDLc, which is included in the 22 reported cholesterol components — all at no additional cost. These components include Lp(a), apoB, apoA1, and the apoB/apoA1 ratio, making the VAP Test the only lipid profile that routinely reports all three lipid parameters — LDL, non-HDL and apoB — considered necessary by the ACC and the American Diabetes Association. The comprehensive lipid profile also identifies markers of metabolic syndrome, often associated with early diabetes.

Atherotech provides clinicians with a single source for the VAP Cholesterol Test and more than a dozen cardiovascular and metabolic tests, including C-Reactive Protein (hsCRP), LpPLA₂, apoE genotype, NT-proBNP, cystatin C, T3 and T4 when TSH is abnormal, plus gamma-glutamyl transferase (GGT), a recognized cardiovascular risk biomarker.

Get updates throughout the conference by following Atherotech on Twitter and Facebook. For more information, visit www.Atherotech.com or call 877.901.8510.

About Atherotech Diagnostics Lab

Atherotech is a CLIA-certified clinical reference laboratory and cardiodiagnostic company focusing on cardiometabolic tests, including the company’s patented VAP Cholesterol Test, which reports the cholesterol content of all lipids, components and subclasses. The VAP Test is the first cholesterol profile to comply with updated National Cholesterol Education Program ATP III recommendations for direct LDLc measurement, which is accurate with non-fasting samples. The VAP Test is available through national and regional diagnostic laboratories and is reimbursed by many of the largest private insurers as well as Medicare. For more information, visit www.Atherotech.com.

For Atherotech Diagnostics Lab
Armada Medical MarketingMicki Sievwright, 303-623-1190 x240
[email protected]

Source: Atherotech Diagnostics Lab